Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 11/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.42 |
| ▸ | MET | P08581 | 7/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23528788 | 0.88 | GRIN2B (0.44) | GRIN2BGRIN1MET | |
| SCHEMBL23528379 | 0.86 | GRIN2B (0.50) | GRIN2BGRIN1MET | |
| SCHEMBL29569798 | 0.86 | GRIN2B (0.50) | GRIN2BGRIN1MET | |
| SCHEMBL30679591 | 0.84 | MET (0.46) | GRIN2BGRIN1METP2RX7 | |
| SCHEMBL23528778 | 0.83 | MET (0.38) | GRIN2BGRIN1METP2RX7 | |
| SCHEMBL27068818 | 0.82 | GRIN1 (0.47) | GRIN2BGRIN1MET | |
| SCHEMBL26529132 | 0.78 | GRIN2B (0.44) | GRIN2BGRIN1MET | |
| SCHEMBL26527929 | 0.78 | GRIN2B (0.44) | GRIN2BGRIN1MET | |
| SCHEMBL26522355 | 0.76 | MET (0.43) | GRIN2BGRIN1MET | |
| SCHEMBL25438256 | 0.76 | MEN1 (0.35) | GRIN2BGRIN1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012395-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4248973-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3877376-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | GRIN2B 1553/4885GRIN1 728/4885MET 4319/4885 |
| US-12012395-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | GRIN2B 1997/4885GRIN1 894/4885MET 4212/4885 |
| US-11873290-B2 | — | IL6, MUSK, IL6ST | GRIN2B 2129/4885GRIN1 959/4885MET 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.